Timely Topics in Transplantation
Timely topics in transplantation presented by expert faculty.
Timely Topics in Transplantation (T3) webinars are the perfect opportunity to listen to a live presentation by expert faculty on a current issue in transplantation. Live attendees are encouraged to participate by submitting questions to help shape the Q&A discussion featured in each session.
What makes the Timely Topics in Transplantation webinar series so relevant to the interests of transplant professionals? T3 webinars are developed by the AST Education Committee in partnership with the AST Communities of Practice. Every year, 7 to 10 new webinars are added to the series, featuring topics identified by COP and Committee leaders as the most important to transplant professionals.
All T3 webinars are $25 per session, but free to AST members as part of their member benefits package. All webinars are available on-demand after the live air date.
The 2024-2025 T3 Webinar Series will feature important topics like:
- "Utilizing GLP-1 Agonists to Improve Access to Solid Organ Transplantation", focusing on the potential uses, safety, and efficacy of these popular weight loss medications in transplant.
- "Xenotransplantation: Pig-to-Human Kidney Transplant", featuring presentations from the experts at Mass General Hospital and NYU Langone.
- "Normothermic Regional Perfusion vs. Ex-Vivo Machine Perfusion: What is the Best Approach to a DCD Donor in 2025?", featuring presentations and discussion on the pros and cons of NRP and MP.
- "The Impact of the New FDA final Rule on Laboratory Developed Tests (LDT) in Transplantation", featuring presentations and discussion on this new rule and the effects it may have on testing and development.
...and more!
Learn more about the best approaches to DCD donors in 2025, including the OPO Perspective on NRP and MP, turning DCD offers into successful transplants, and operational costs and risks.
Learn more about a recent FDA rule revision and the potential effect it may have on the development of new diagnostic assays, particularly affecting molecular diagnostics and testing in transplantation.
Learn more about the latest in Xenotransplantation, Pig-to-Human Kidney Transplant, from the experts in the field.
On-demand: T3 Series
Browse the T3 series by year.
The 2023-2024 T3 Series
Covering A.I. & Transplantation, Phage Therapy in SOT, DCUs, Post-transplant Malignancy Treatments, and more.
The 2022-2023 T3 Series
Covering Medicare Part B-ID, Donor-Derived Infections, Care of the Transgender Recipient, Xenotransplantation, and more.
The 2021-2022 T3 Series
Covering Management of Multidrug Resistant Organisms, Xenotransplantation: Pig to Human Heart Transplant, and more.
The 2020-2021 T3 Series
Covering Biomarkers and Gene Expression, Optimizing Vaccination, Frailty, and more.
The 2019-2020 T3 Series
Covering Non-invasive Biomarkers, Diagnostic Stewardship, Advanced Technology in Transplant Care, and more.
The 2018-2019 T3 Series
Covering Living Kidney Donation, Pharmacogenomics,, QAPI, an more.
The 2017-2018 T3 Series
Covering Optimizing Viral Diagnostics, Vaccinations, and more.
The 2015-2016 T3 Series
Covering Management of Immunosuppression, Donor-specific Antibody Testing, and more.
The 2014-2015 T3 Series
Covering Hep C Treatment in SOT Recipients, Monitoring Alloresponse, and more.
Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk.
Advertisements
